An enzymatic method for the measurement of glycated albumin in biological samples

Kouzuma, Takuji; Usami, Tomomi; Yamakoshi, Masaru; Takahashi, Mamoru; Imamura, Shigeyuki

doi:10.1016/s0009-8981(02)00207-3

Cited by 199 publications

(160 citation statements)

References 20 publications

Supporting

Mentioning

153

Contrasting

Unclassified

Order By: Relevance

“…Serum GA was determined by enzymatic method using albumin-specific protease, ketoamine oxidase and albumin assay reagent (Lucica GA-L; Asahi Kasei Pharma, Tokyo, Japan). 20,21 GA was hydrolyzed to amino acids by an albumin-specific proteinase, and then oxidized by ketoamine oxidase to produce hydrogen peroxide, which was measured quantitatively. Serum GA levels were calculated as the percentage of GA relative to total albumin, which was measured in the same serum sample using a new bromocresol purple method.…”

Section: Discussionmentioning

confidence: 99%

Measurement of glycated hemoglobin and glycated albumin in umbilical cord: evaluation of the glycemic control indicators in neonates

et al. 2010

View full text Add to dashboard Cite

Objective: As neonatal blood contains a high proportion of fetal hemoglobin (HbF), it is difficult to use high-performance liquid chromatography (HPLC) method, latex-immunoturbidimetry (LA) method and enzymatic methods, which determine hemoglobin A 1C (HbA 1C ) in order to provide the glycemic control indicators of neonates. In this study, we evaluated glycated hemoglobin (GHb) and glycated albumin (GA) as appropriate indicators of the glycemic control in the neonatal period.Study Design: Umbilical cord blood samples collected during delivery were subjected to measurements of GHb (HPLC methods using two different instruments, LA method, enzymatic method and affinity method) and serum GA.Result: HbA 1C levels determined by the HPLC method, the LA method and the enzymatic method were as low as <3.0% in all the cases. Although GHb determined by the affinity method was 3.6 ± 0.2%, this method may not measure accurately the values of glycated HbF plus glycated HbA. Serum GA was 9.4 ± 1.1%. Conclusion:We speculate that serum GA, but not GHb, could be used as glycemic control indicators in neonates.

show abstract

Section: Discussionmentioning

confidence: 99%

Measurement of glycated hemoglobin and glycated albumin in umbilical cord: evaluation of the glycemic control indicators in neonates

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Historically, fructosamine has been used in clinical practice when a short-term glycemia evaluation is needed (12,28). However, this test presents low accuracy since it is influenced by all plasma proteins and also by other molecules present in the blood, such as bilirubin, uric acid and low molecular weight substances (12).…”

Section: Laboratory Measurement Of Gamentioning

confidence: 99%

“…However, this test presents low accuracy since it is influenced by all plasma proteins and also by other molecules present in the blood, such as bilirubin, uric acid and low molecular weight substances (12). Further, fructosamine is not available at all laboratories (18,29) and there are no well-established international standards for its use.…”

Section: Laboratory Measurement Of Gamentioning

confidence: 99%

“…An enzymatic methodology with a shorter operational time and easier to perform both manually and automatically was proposed to evaluate the GA levels in order to overcome the limitations of the previously existing techniques (12). This method presents three steps (Figure 2), using specific proteinase for albumin and ketamine oxidase, besides the bromocresol green reagent for albumin determination and later calculation of %GA.…”

Section: Laboratory Measurement Of Gamentioning

confidence: 99%

“…GA is one of the fructosamines, but it has the advantage of not being influenced by the concentration of other serum proteins since it is specific to the albumin glycation rates (12). Further, GA does not require fasting for its measurement and reflects short-term glycemia due to the half life time of the albumin, which is approximately 3 weeks.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Glycated albumin: a potential biomarker in diabetes

Freitas

Ehlert

Camargo

2017

Arch. Endocrinol. Metab.

136

103

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a chronic and metabolic disease that presents a high global incidence. Glycated hemoglobin (A1C) is the reference test for long-term glucose monitoring, and it exhibits an association with diabetic chronic complications. However, A1C is not recommended in clinical situations which may interfere with the metabolism of hemoglobin, such as in hemolytic, secondary or iron deficiency anemia, hemoglobinopathies, pregnancy, and uremia. The glycated albumin (GA) is a test that reflects short-term glycemia and is not influenced by situations that falsely alter A1C levels. GA is the higher glycated portion of fructosamine. It is measured by a standardized enzymatic methodology, easy and fast to perform. These laboratory characteristics have ensured the highlight of GA in studies from the last decade, as a marker of monitoring and screening for DM, as well as a predictor of long-term outcomes of the disease. The aim of this review was to discuss the physiological and biochemistry characteristics of the GA, as well as its clinical utility in DM. Arch Endocrinol Metab.2017;61(3):296-304.

show abstract

Biomarkers for Insulin Resistance and Inflammation and the Risk for All-Cause Dementia and Alzheimer Disease

et al. 2012

View full text Add to dashboard Cite

An enzymatic method for the measurement of glycated albumin in biological samples

Cited by 199 publications

References 20 publications

Measurement of glycated hemoglobin and glycated albumin in umbilical cord: evaluation of the glycemic control indicators in neonates

Measurement of glycated hemoglobin and glycated albumin in umbilical cord: evaluation of the glycemic control indicators in neonates

Glycated albumin: a potential biomarker in diabetes

Biomarkers for Insulin Resistance and Inflammation and the Risk for All-Cause Dementia and Alzheimer Disease

Contact Info

Product

Resources

About